Market Signal Briefing

December 07, 2025 8:52 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in DeFi Technologies to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in DeFi Technologies between May 12, 2025 and November 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DeFi Technologies Inc. ("DeFi Technologies" or the "Company") (NASDAQ: DEFT) and reminds investors of the January 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (ii) DeFi Technologies had understated the extent of competition it faced from other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly, Defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies' business and financial results; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On November 6, 2025, DeFi Technologies issued a press release purporting to report an arbitrage trade by DeFi Alpha. The press release disclosed, inter alia, that "[DAT]s have absorbed or delayed a significant share of arbitrage opportunities over the past year."

On this news, DeFi Technologies' stock price fell $0.13 per share, or 7.43%, to close at $1.62 per share on November 6, 2025.

Then, on November 14, 2025, DeFi Technologies issued a press release reporting its financial results for the third quarter of 2025. Among other items, DeFi Technologies reported a revenue decline of nearly 20%, falling well short of market expectations. The Company also significantly lowered its 2025 revenue forecast, from $218.6 million to approximately $116.6 million, and attributed this reduction to "a delay in executing DeFi Alpha arbitrage opportunities previously forecasted due to the proliferation of [DAT] companies and the consolidation in digital asset price movement in the latter half of 2025."

Concurrently, DeFi Technologies announced that Defendant Newton would leave his role as CEO and transition to an advisory position.

Following these disclosures, DeFi Technologies' stock price fell $0.40 per share, or 27.59%, over the following two trading sessions, to close at $1.05 per share on November 17, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding DeFi Technologies's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the DeFi Technologies class action, go to www.faruqilaw.com/DEFT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277111

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.

So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the MoonLake Immunotherapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or mailto:call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors.

On November 14, New York City-based Newtyn Management disclosed a purchase of 994,332 shares of QuidelOrtho Corporation (QDEL), increasing its stake by approximately $30.4 million.

What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Newtyn Management reported buying 994,332 additional shares of QuidelOrtho Corporation (QDEL) during the third quarter. This raised its total position to 2.7 million shares with a reported value of $79.5 million as of September 30.

What Else to KnowThe fund's QDEL stake now represents 9.7% of its $816.9 million in 13F reportable assets.

Top holdings after the filing: 

NASDAQ:INDV: $101.3 million (12.4% of AUM)NASDAQ:QDEL: $79.5 million (9.7% of AUM)NASDAQ:TBPH: $72.3 million (8.8% of AUM)NYSE:AD: $67.5 million (8.3% of AUM)NYSE:CNNE: $62.5 million (7.6% of AUM)As of November 14, QDEL shares were priced at $27.76, down 26% over the past year and well underperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValueRevenue (TTM)$2.7 billionNet Income (TTM)($1.2 billion)Price (as of Friday)$27.761-Year Price Change(26%)Company SnapshotQuidelOrtho Corporation develops and manufactures diagnostic testing technologies, including clinical chemistry instruments, immunoassay systems, blood typing and donor screening tools, and point-of-care and molecular diagnostic products.The company generates revenue through direct sales and distribution of diagnostic equipment and consumables to healthcare providers, laboratories, blood banks, and retail channels.It serves hospitals, clinical and reference laboratories, urgent care and retail clinics, blood banks, donor centers, and international markets in North America, EMEA, China, and beyond.QuidelOrtho Corporation is a leading provider of diagnostic testing solutions, operating at scale with a global footprint and a diversified product portfolio. The company leverages expertise in laboratory, transfusion medicine, point-of-care, and molecular diagnostics to address a broad range of healthcare testing needs.

Its strategy centers on innovation in diagnostic technologies and expanding access to rapid and accurate testing for both professional and consumer markets. This diversified approach supports resilience and positions the company as a key player in the global diagnostics industry.

Foolish TakeLong-term investors will likely view Newtyn’s move as a high-conviction bet on a deeply discounted diagnostics play trying to reset its fundamentals after a turbulent few years. QuidelOrtho’s shares have shed nearly 90% of their value since 2020, but the company’s latest quarter showed signs of stabilization in its core business even as headline results were overshadowed by a $701 million goodwill impairment tied to its lower market valuation. Beneath that non-cash charge, non-respiratory revenue grew 5% as reported, lab revenue increased 5%, and adjusted EBITDA margin expanded to 25%, up 180 basis points from last year.

For a value-oriented fund like Newtyn—whose portfolio already skews toward complex special situations—doubling down on QDEL fits a pattern: leaning into distressed but cash-generating companies with pathways to operational improvement. With adjusted EPS of $0.80, rising cost efficiencies, and narrowed full-year guidance, the underlying trajectory may look more durable than the stock chart suggests. Ultimately, it'll be important to watch whether margin gains continue as COVID revenue declines stabilize, and whether the company can maintain growth in labs, immunohematology, and point-of-care as it winds down donor screening.

Glossary13F: A quarterly report filed by institutional investment managers to disclose their equity holdings.
Assets Under Management (AUM): The total market value of investments managed by a fund or firm on behalf of clients.
Stake: The ownership interest or share held in a company by an investor or fund.
Holding: A security or asset owned by an investor or fund.
Filing: An official submission of required documents or reports to a regulatory authority, such as the SEC.
Point-of-Care: Medical testing performed at or near the site of patient care rather than in a centralized laboratory.
Molecular Diagnostics: Techniques that analyze biological markers in the genome and proteome to diagnose and monitor disease.
Consumables: Products that are used up during diagnostic testing, such as reagents or test cartridges.
Transfusion Medicine: The branch of medicine focused on the transfusion of blood and blood components.
EMEA: Geographic region including Europe, the Middle East, and Africa.
13F Reportable Assets: Securities that must be disclosed in a fund's 13F filing with the SEC.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends QuidelOrtho. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeETFs and Funds AnalysisETF Analysis

SummaryThe Schwab Fundamental U.S. Small Company ETF offers diversified small-cap exposure with fundamental weighting, contrasting VUG's concentrated large-cap technology focus.VUG's top 10 holdings comprise 60.9% of assets, with 63.3% of the ETF in technology, exposing it to significant sector-specific downside risk.FNDA's valuation appears relatively attractive versus the Russell 2000 and S&P 500, though not cheap in absolute terms; it lags VUG's recent performance.I rate FNDA a hold, favoring SMDV for defensiveness, but recommend reducing VUG and adding FNDA or VBR for diversification.pepifoto/iStock via Getty Images

This piece follows up a similar idea that I shared last month, to sell VTI and buy VBR. Since that article was published, both ETFs are up about the same. The big idea from that article was to

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

HomeStock IdeasLong IdeasBasic Materials

SummaryRio Tinto is regaining internal order. Q3 showed stable operations, clearer execution, and a simplified structure that finally aligns decisions with scale and reduces noise that previously clouded the investment case.The shift to three product groups improves focus, accountability, and long-term efficiency, reinforcing a strategic direction that was missing months ago and giving more coherence to a business often viewed.Strong margins, a 5% dividend yield, and an undemanding 11x P/E show a valuation still anchored in last semester’s weakness, not in the operational discipline and clarity emerging through recent events.Risks remain, mainly iron dependence and project execution, but the combination of better internal alignment, stable production, and a discounted multiple strengthens the risk-reward, supporting my decision to move to buy.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS).

Anthony Scaramucci joins The Watch List to talk about his new book, 'Solana Rising,' and why the cryptocurrency will be one of the biggest market stories over the next five years. He takes investors through the altcoin space and the opportunities he sees in crypto beyond Bitcoin.

December 07, 2025 8:03 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Blue Owl to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in Blue Owl between February 6, 2025 and November 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Blue Owl Capital Inc. ("Blue Owl" or the "Company") (NYSE: OWL) and reminds investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Blue Owl was experiencing a meaningful pressure on its asset base from BDC redemptions; (2) that, as a result, the Company was facing undisclosed liquidity issues; (3) that, as a result, the Company would be likely to limit or halt redemptions of certain BDCs; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On November 16, 2025, the Financial Times published an article describing how "Blue Owl has blocked redemptions in one of its earliest private credit funds as it merges with a larger vehicle overseen by the asset manager in a deal that could leave investors with large losses."

According to the report, Blue Owl Capital Corporation II investors are restricted from pulling money from the fund until a recently announced merger with Blue Owl Capital Corporation closes in early 2026.

The article further explains how, once the merger occurs, investors in Blue Owl Capital Corporation II will permanently lose the ability to redeem cash at the fund's Net Asset Value (NAV). Instead, investors will trade their shares in for the publicly traded Blue Owl Capital Corporation shares, which are currently trading approximately 20% under the fund's NAV.

On this news, Blue Owl's stock price fell $0.85, or 5.8%, to close at $13.77 per share on November 17, 2025, thereby injuring investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Blue Owl's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Blue Owl Capital class action, go to www.faruqilaw.com/OWL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277108

December 07, 2025 08:05 ET

 | Source:

Prime Medicine, Inc.

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company’s investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The data will also be presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida.

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, biological activity and preliminary efficacy in adult and pediatric study participants. Both patients experienced rapid neutrophil and platelet engraftment, as well as durable restoration of NADPH oxidase activity and early clinical benefit, without any safety concerns. Together, these results provide the first-in-human demonstration of the safety and efficacy of Prime Editing, and support the potential for PM359 as a precise therapeutic strategy for CGD:

Both patients enrolled in the study had a history of prior CGD-defining complications, including CGD-associated colitis (CAC), and skin and soft tissue infections, and both were maintained on long-term prophylactic therapy.Both patients experienced rapid neutrophil engraftment, achieving 69% and 83% dihydrorhodamine-positive (DHR+) neutrophils by Day 30, respectively, far in excess of the 20% projected minimum threshold for clinical benefit. DHR activity remained stable over time in both patients, suggesting that gene correction occurred in the long-term repopulating hematopoietic stem cells (HSCs) of the bone marrow.Both patients remain free of new CGD-related complications or significant intercurrent illnesses post-infusion; additionally, Patient 1 stopped his mesalamine treatment and has not experienced a flare of CAC, and Patient 2’s levels of fecal calprotectin have decreased substantially, and his chronic CAC symptoms have abated.No clinically significant adverse events attributable to PM359 occurred in either patient, and all observed toxicities were consistent with busulfan-based conditioning. “Publication of these first-in-human data highlights Prime Editing’s promise as a next-generation therapeutic platform, which is capable of delivering meaningful benefits to patients and which can be manufactured and delivered at clinical scale,” said Mohammed Asmal, M.D., Ph.D., Chief Medical Officer of Prime Medicine. “Beyond demonstrating early clinical efficacy, these results offer important insights into Prime Editing’s safety profile and potential advantages over other gene editing technologies. As described in the NEJM publication, we observed high recovery rates of viable corrected cells after a single mobilization cycle, as well as the rapid reconstitution of the hematopoietic system after infusion. Both support our belief that the mechanism of Prime Editing, which does not induce double-strand breaks, may be better tolerated by HSCs and other cell types – and therefore safer for patients – than other approaches.”

About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the significance of data from its Phase 1/2 trial of PM359; the potential for PM359 to be a precise and safe therapeutic strategy for CGD;; the safety and efficacy of Prime Editing, including in comparison to other approaches; the potential of Prime Editing to correct the causative mutations of, and to cure, diseases; its strategic plans for its business, programs, and technology; and the potential of Prime Editing to unlock opportunities across thousands of potential indications.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to Prime Medicine’s product candidates entering clinical trials; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology; Prime Medicine’s ability to identify and enter into future license agreements and collaborations; Prime Medicine’s expectations regarding the anticipated timeline of its cash runway and future financial performance; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
[email protected] 

Hannah Deresiewicz
Precision AQ
212-362-1200
[email protected]

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Costco Wholesale Corporation (NASDAQ: COST) and Walmart Inc. (NYSE: WMT) both closed out strong quarters recently, revealing two very different strategies for winning in retail. Costco leaned into its membership warehouse model with e-commerce expansion. Walmart went all-in on omnichannel transformation and marketplace growth.

E-Commerce Growth Tells Two Different Stories
Walmart’s digital business exploded 27% in Q3, driven by store-fulfilled delivery, marketplace expansion, and aggressive investments in digital infrastructure. The company spent $18.6 billion on capital expenditures this year, much aimed at logistics and technology supporting same-day delivery and pickup. CFO John David Rainey emphasized “enhancing the digital customer experience” during the earnings call.

Costco’s e-commerce grew 13.6% in Q4, solid but far slower than Walmart’s pace. The company operates 914 warehouses globally and continues prioritizing the in-store bulk buying experience that defines its model. E-commerce supports the core business rather than transforming it. Comparable sales rose across all regions.

Walmart’s international segment jumped 10.8% to $33.5 billion in net sales, while Sam’s Club added $23.6 billion with 3.1% growth. The breadth of Walmart’s portfolio gives it more levers to pull when one segment softens.

Membership Model vs. Omnichannel Flexibility
Costco’s strategy revolves around membership fees and bulk purchasing. The model creates predictable revenue and keeps customers locked into the ecosystem. Net income grew 10.9% to $2.61 billion, and profit margin held at 2.94%. Operating margin of 3.88% reflects the thin-margin, high-volume approach that has worked for decades.

Walmart’s net income surged 33.0% to $6.09 billion, though operating income stayed flat due to share-based compensation charges related to PhonePe. The company raised full-year guidance to adjusted EPS of $2.58 to $2.63. Gross margin grew slower than revenue, indicating pricing pressure, but scale and diversification provide cushion.

Metric
Costco
Walmart

E-Commerce Growth
13.6%
27%

Net Income Growth
10.9%
33.0%

Operating Margin
3.88%
3.73%

P/E Ratio
49.02
40.39

Walmart’s marketplace and digital infrastructure give it flexibility Costco doesn’t have. Costco’s warehouse model limits how fast it can scale and where it can compete. But that constraint also creates discipline.

What I’m Watching Into 2026
I will be watching whether Walmart can sustain 27% e-commerce growth without crushing margins further. The capital spending is massive, and the payoff needs to show up in profitability soon. Costco’s challenge: can it accelerate digital growth without diluting the membership value proposition?

Walmart’s international strength and Sam’s Club stability give it more ways to win if U.S. retail softens. Costco’s global footprint is solid but less diversified. Both companies face input cost volatility and consumer spending uncertainty heading into 2026.

Why I Lean Toward Walmart for Growth Investors
If you want a turnaround story with momentum, Walmart looks more compelling right now. The 33% net income growth and 27% e-commerce surge show the digital transformation is working. The stock trades at 40x earnings compared to Costco’s 49x, offering better value for the growth rate.

Costco fits defensive investors better. As one Reddit user put it: “For me, my best investment was probably Costco. I bought in March during that random dip and just held. Boring but solid.” That sums up the appeal. Steady, predictable, reliable.

Walmart may appeal more to investors focused on omnichannel retail growth and digital transformation. Costco may fit better for those prioritizing stability and the proven membership model during economic volatility.

It would currently cost investors starting from scratch over $11,000.

One of the better parts of investing in stocks is the passive income you can receive from owning dividend stocks or exchange-traded funds (ETFs). It's a way of receiving value from your stocks without relying solely on stock price appreciation, though both are appreciated.

A popular go-to dividend ETF is the SPDR Portfolio S&P 500 High Dividend ETF (SPYD 0.16%), which has a trailing yield of 4.46% at the time of this writing. At that yield, you'd need to own about 256 shares of SPYD to receive $500 in annual dividend income. At its current price of $43.86 per share, that would cost you around $11,210.

Image source: Getty Images.

SPYD's 4.46% dividend yield is among the higher yields you'll find in a broad dividend ETF, but it makes sense given that the ETF tracks the top 80 high-dividend-yielding companies in the S&P 500 (an index of the 500 largest American companies).

Today's Change

(

-0.16

%) $

-0.07

Current Price

$

43.40

By investing in a high-yielding dividend ETF like SPYD, you get a payout that's close to four times higher than the S&P 500 average, exposure to 78 companies spanning all 11 major U.S. sectors, and a cheap ETF whose expense ratio is only 0.07%. The latter works out to paying only $0.70 per $1,000 invested in SPYD, which is easily made up by the dividends you receive.

Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

December 07, 2025 8:10 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Baxter between February 23, 2022 and Ocober 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.

The true extent of Defendants' fraud was revealed on July 31, 2025, when the Company announced that it had decided to "voluntarily and temporarily pause shipments and planned installations of the Novum LVP" and that the Company was "unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs." On this news, Baxter stock dropped 22.4 percent, closing at $21.76 on July 31, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Baxter's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Baxter International class action, go to www.faruqilaw.com/BAX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277106

December 07, 2025 8:17 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Avantor To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avantor, Inc. ("Avantor" or the "Company") (NYSE: AVTR) and reminds investors of the December 29, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Avantor's competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants' representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

During the Class Period, Defendants misled investors by falsely touting the Company's competitive positioning and downplaying the effects of increased competition. For example, during an earnings call on July 26, 2024, in response to an analyst's question about whether Avantor was losing share to a competitor, Defendant Michael Stubblefield, then the Company's President and Chief Executive Officer, assured investors that Avantor's "lab business stacks up well against every number that certainly that we've seen," that "we continue to enhance our position," and that "we're really confident in our value proposition and our competitive position." Likewise, Defendants repeatedly pointed to Avantor's purported competitive advantages, such as its digital capabilities, as evidence that the Company would continue to enjoy strong competitive positioning.

Investors began to learn the truth about the effects of increased competition on Avantor's business on April 25, 2025, when the Company reported disappointing first quarter 2025 financial results, cut its guidance for 2025, and announced that Defendant Stubblefield would be stepping down from his roles as President and Chief Executive Officer. Defendants attributed Avantor's weak performance and outlook to "the impact of increased competitive intensity."

On this news, the price of Avantor common stock declined $2.57 per share, or more than 16.5%, from a close of $15.50 per share on April 24, 2025, to close at $12.93 per share on April 25, 2025

Then, on August 1, 2025, the Company reported disappointing second quarter 2025 financial results, including a year-over-year decrease in net sales, and further reduced the Company's 2025 guidance-now projecting organic revenue growth of -2% to 0%. Defendants again attributed Avantor's poor results and outlook to "increased competitive intensity," and further admitted that the Company did not expect the competitive environment to materially improve in the remainder of 2025 and weak performance would therefore likely persist.

In response to this news, the price of Avantor common stock declined $2.08 per share, or more than 15%, from a close of $13.44 per share on July 31, 2025, to close at $11.36 per share on August 1, 2025.

Then, on October 29, 2025, the Company reported weak third quarter 2025 financial results, including -5% organic revenue growth (below the guidance Defendants had provided in August), and a net loss of $712 million, which Defendants primarily attributed to a non-cash goodwill impairment charge of $785 million. Defendants revealed that the impairment charge was necessary due in part to "competitive pressures" that had "meaningfully impacted" the Company's margins, and further admitted that the Company had lost several large accounts

On this news, the price of Avantor common stock declined $3.50 per share, or more than 23%, from a close of $15.08 per share on October 28, 2025, to close at $11.58 per share on October 29, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Avantor's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Avantor class action, go to www.faruqilaw.com/AVTR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277105

December 07, 2025 8:20 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In James Hardie To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in James Hardie between May 20, 2025 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against James Hardie Industries plc ("James Hardie" or the "Company") (NYSE: JHX) and reminds investors of the December 23, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, the company falsely claimed demand remained strong and that stock levels were "normal."

On August 19, 2025, James Hardie issued a press release announcing financial results for its first quarter ended June 30, 2025. Among other items, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings, citing high borrowing costs.

On this news, James Hardie's American Depositary Receipt ("ADR") price fell $9.79 per ADR, or 34.44%, to close at $18.64 per ADR on August 20, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding James Hardie's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the James Hardie class action, go to www.faruqilaw.com/JHX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277118

December 07, 2025 8:21 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Bitdeer to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bitdeer Technologies Group ("Bitdeer" or the "Company") (NASDAQ: BTDR) and reminds investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that among other things, confidence in the Company's mass-production of its fourth-generation SEALMINER (A4) rigs using its SEAL04 ASIC (application-specific integrated circuit) chip technology was expected to have a chip energy efficiency of as low as 5J/TH. Defendants provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of Bitdeer's SEALMINER A4 project. Specifically, Defendants failed to disclose that the SEAL04 chip projected to have a chip-level energy efficiency of 5 J/TH would be ready for use in the A4 rigs with an expected mass production to begin in the second quarter 2025. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Bitdeer's securities at artificially inflated prices.

On November 10, 2025, Bitdeer issued a press release reporting its unaudited financial results for the third quarter of 2025. Among other items, Bitdeer reported earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22. Bitdeer also disclosed that "development of [its] next-generation Seal 04 [ASIC chip] is significantly delayed."

On this news, Bitdeer's stock price fell $2.63 per share, or 14.9%, to close at $15.02 per share on November 11, 2025.

Then, on November 12, 2025, Bitdeer issues a press release "reporting a fire incident at its under-construction facility in Massillon, Ohio." According to the press release, "[t]he fire incident occurred on the afternoon of November 11" and "2 of the 26 buildings currently under construction sustained fire damage."

On this news, Bitdeer's stock price fell another $2.83 per share, or 20.3%, to close at $11.11 per share on November 13, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Bitdeer's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Bitdeer Technologies class action, go to www.faruqilaw.com/BTDR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277107

December 07, 2025 8:27 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Nidec to Contact Him Directly to Discuss Their Options

If you suffered significant losses in Nidec stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nidec Corporation ("Nidec" or the "Company") (OTC: NJDCY).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On September 3, 2025, Nidec disclosed it had established a third-party committee to investigate suspicions of improper accounting. The Company further revealed its "investigations found multiple documents suggesting that . . . the Company and its group companies could have engaged in improper accounting with the involvement or knowledge of its or their management[.]"

On this news, Nidec's stock price fell $0.81, or 16.5%, to close at $4.11 per share on September 4, 2025, thereby injuring investors.

Then, on September 26, 2025, Nidec disclosed further investigative findings of additional suspected inappropriate accounting practices, including "cases where the reported value for customs purposes was declared to be lower than the appropriate amount without legitimate reason." The Company also revealed that it "received an audit report containing a disclaimer of opinion" from its auditor due to the "ongoing investigations by the third-party committee, other internal investigations, and other action[s]."

On this news, Nidec's stock price fell $0.29, or 6.6%, to close at $4.09 per share on September 26, 2025.

Then, on October 23, 2025, Nidec published a press release announcing that it was withdrawing its year end forecast, and had decided not to pay a surplus dividend as "investigations by the Third Party Committee regarding suspected inappropriate accounting practices involving the Company and its group, as well as other internal investigations, are ongoing."

On this news, Nidec's stock price fell $1.17, or 25.4%, to close at $3.43 on October 23, 2025.

Finally, on October 27, 2025, the Tokyo Stock Exchange ("TSE") designated Nidec under a Special Security alert in part because "TSE deems that the improvement of the internal management system of said listed company is highly necessary." The alert noted that "[s]ince the initial issue was discovered, the scope of the investigation has continued to expand" and that "deficiencies have already been identified in the Company's company-wide internal control systems (particularly in areas related to information and communication), as well as in the internal controls related to its accounting and financial closing processes."

On this news, Nidec's stock price fell $0.80, or 20.3%, to close at $3.15 per share on October 27, 2025, thereby injuring investors further.

To learn more about the Nidec investigation, go to www.faruqilaw.com/NJDCY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277120

December 07, 2025 8:29 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Marex to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marex Group plc ("Marex" or the "Company") (NASDAQ: MRX) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex's financial statements could not be relied upon; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 5, 2025, NINGI Research released a report accusing Marex of a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits. The report cited examples such as a $17 million fabricated receivable, inflated subsidiary profits, and undervalued asset sales. It also alleged that Marex concealed nearly $1 billion in derivatives exposure through a Luxembourg fund used to create fake profits and boost cash flow.

Following the report, Marex's stock dropped 6.2%, closing at $35.31 on heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Marex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Marex Group plc class action, go to www.faruqilaw.com/MRX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277114

December 07, 2025 8:30 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Freeport-McMoran To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Freeport between February 15, 2022 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Freeport-McMoran Inc. ("Freeport" or the "Company") (NYSE: FCX) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Freeport did not adequately ensure safety at the Grasberg Block Cave mine in Indonesia;(2)the lack of proper safety precautions constituted a heightened risk that could foreseeably lead to the death of Freeport's workers; (3) this constituted an undisclosed heightened risk of regulatory, litigation, and reputational risk; and (4) as a result, Defendants' statements about Freeport-McMoRan's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On September 9, 2025, Freeport disclosed it was suspending mining activities at its Grasberg Block Cave operation in Indonesia, after "a large flow of wet material" trapped seven workers.

On this news, Freeport's stock price fell $2.77, or 5.9%, to close at $43.89 per share on September 9, 2025, thereby injuring investors.

Then, on September 24, 2025, Freeport provided an update on the incident, disclosing that two of the trapped team members "were regrettably fatally injured[.]" Meanwhile, "extensive efforts" remained "ongoing in the search for [the five] team members who [remained] missing."

On this news, Freeport's stock price fell $7.69, or 17%, to close at $37.67 per share on September 24, 2025.

Then, on September 25, 2025, before market hours, Bloomberg published an article stating that the "halt in production at the giant Grasberg copper mine in Indonesia looks set to strain the fractious relationship between [Freeport] and its host nation, at a time when the Jakarta government was already looking to take greater control." The article specified that "[the] state controls 51% of the local entity - after a lengthy battle over ownership - but officials have sporadically continued to demand an increased share. That clamor may now intensify."

On this news, Freeport's stock price fell $2.33, or 6.2%, to close at $35.34 on September 25, 2025, thereby injuring investors further.

On September 28, 2025, a news organization focusing on Indonesia, published an article entitled "Freeport Landslide was Preventable, Not Just a Natural Disaster, Says Expert." The article quoted an expert as saying "this danger is not new and should have been anticipated from the beginning[.]"

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Freeport's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Freeport-McMoran class action, go to www.faruqilaw.com/FCX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277115

December 07, 2025 8:42 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In CarMax To Contact Him Directly To Discuss Their Options

If you suffered losses in CarMax between June 20, 2025 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CarMax, Inc. ("CarMax" or the "Company") (NYSE: KMX) and reminds investors of the January 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants recklessly overstated CarMax's growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, defendants statements about CarMax's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On September 25, 2025, the Company released its second quarter fiscal 2026 financial results, disclosing that "[CarMax Auto Finance, or CAF] income decreased 11.2%" due to a $142.2 million provision for loan losses in the second quarter of fiscal 2026 compared to $112.6 million in the prior year's second quarter. Further, the Company stated that "[t]he provision for loan losses in the second quarter of 2026 included an increase of $71.3 million in our estimate of lifetime losses on existing loans, primarily due to worsening performance among the 2022 and 2023 vintages" and that "[t]he remaining $70.9 million reflected our estimate of lifetime losses on current quarter originations."

Following this news, the price of CarMax stock fell $11.45 per share, approximately 20%, to close at $45.60 per share on September 26, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding CarMax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the CarMax class action, go to www.faruqilaw.com/KMX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277109

This AI infrastructure stock deserves a lot more attention.

Credo Technology (CRDO 2.70%), a provider of high-speed connectivity solutions for data centers, has generated massive gains since its initial public offering (IPO). It went public at $10 per share on Jan. 26, 2022, opened at $12.10 on the first day, but now trades at about $177.

The stock skyrocketed as it dazzled the bulls with its explosive growth and direct exposure to the booming artificial intelligence (AI) market. But it usually isn't mentioned in the same breath as other top AI stocks like Nvidia and Palantir Technologies.

So can Credo, which already rallied more than 150% over the past 12 months, maintain its momentum in 2026 as the AI market expands? Let's review its business model and near-term catalysts to find out.

Image source: Getty Images.

What does Credo do?
Credo sells active electrical cables (AECs), which connect switches, servers, and other hardware across data centers; serializer/deserializer (SerDes) chiplets, which convert serial and parallel data across high-bandwidth connections; and other types of integrated circuits and digital signal processor chips for optical and electrical connections.

Its high-speed connectivity products are essentially the "plumbing fixtures" of modern data centers, which makes them essential purchases for companies that want to upgrade their infrastructure to support the latest cloud and AI applications. It also licenses its IP to other companies.

Credo says its products "ease system bandwidth bottlenecks" in data centers. Its new 224G PAM4 SerDes chiplets, which were built on Taiwan Semiconductor Manufacturing's advanced N3 (3nm) node, help data centers achieve port connectivity speeds of 1.6 Tbps -- a crucial threshold for supporting next-gen AI clusters and hyperscale data centers.

Today's Change

(

-2.70

%) $

-4.88

Current Price

$

176.04

How fast is Credo growing?
In fiscal 2025 (ended this past May), Credo generated 94% of its revenue from its product sales. The remaining 6% came from its engineering services and IP licensing segment. Its growth slowed down in fiscal 2024 as it geared up for the launches of its faster products (including the 224G PAM4) and generated lower IP licensing revenues.

But in fiscal 2025, its growth accelerated again and its adjusted margins expanded to record highs. That acceleration was driven by the explosive growth of the AI market, which drove its hyperscale data center customers to ramp up their purchases of its AECs, SerDes chiplets, and other chips to increase their bandwidth.

Metric

FY 2022

FY 2023

FY 2024

FY 2025

Revenue growth

81%

73%

5%

126%

Adjusted gross margin

60.6%

58%

62.5%

65%

Adjusted operating margin

N/A*

3.5%

1.4%

26.4%

Data source: Credo Technology. *Not disclosed. FY=fiscal year.

In the first half of fiscal 2026, Credo's revenue surged 273% year over year to $491 million, its adjusted gross margin expanded 430 basis points to 67.6%, and its adjusted operating margin jumped from 7.9% to 44.9%. Adjusted net income rose nearly ninefold to $226 million, and it stayed profitable on a generally accepted accounting principles (GAAP) basis. For the third quarter, Credo expects its revenue to rise 148%-156% year over year as its adjusted gross margin rises from 63.8% to 64%-66%.

For fiscal 2026, analysts expect its revenue and adjusted EPS to surge 173% and 301%, respectively. For fiscal 2027, analysts expect its revenue and adjusted EPS to rise another 37% and 30%, respectively, as the AI boom continues. It's also expected to sell more high-speed optical connectivity chips, retimers (which recover, recondition, and retransmit signals), active LED cables, and gearboxes to reduce its long-term dependence on its core AEC hardware business.

Will Credo remain a top AI play for 2026 and beyond?
Credo established an early-mover advantage in the AI infrastructure space, but it could face tougher competition from more diversified chipmakers like Broadcom and Marvell Technology over the next few years. Customer concentration is another major issue. Four of its hyperscale customers each accounted for more than 10% of its revenue in the second quarter of fiscal 2026, so losing any of those customers could abruptly throttle its growth.

Credo should continue to expand, but investors shouldn't expect it to keep growing by triple digits. Its stock certainly isn't cheap at 93 times its forward adjusted earnings, but it also isn't trading at meme stock levels yet. So if you expect the AI market to keep expanding in 2026 and beyond, it might be a good idea to accumulate a few shares of Credo today. It will remain volatile, but its long-term tailwinds are too strong to ignore.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NVDA, AVGO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), has today announced it will present updated data from a Phase 1/2a trial of the multispecific T-cell engager MP0533 in patients with acute myeloid leukemia (AML) in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.

Merck (MRK 1.16%) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than $100.

What gives? And more importantly, is the recent rebound a sign that the pharmaceutical giant's stock is a buy? Here's what you need to know.

Merck's double-edged dilemma
Merck is a drugmaker with more than 40 different products currently on the market, collectively generating annual revenue of roughly $70 billion. The company is one of the pharma industry's biggest players, in fact.

Today's Change

(

-1.16

%) $

-1.17

Current Price

$

99.72

But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to be something of a miracle drug due to its efficacy as well as its versatility; it's now approved to treat 20 different types of cancer.

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in 2014, its patent protection will begin expiring in 2028. This will allow competitors to make and sell the same drug at a much lower cost, posing a threat to a huge piece of Merck's top line.

That's the chief reason for the stock's steep sell-off over most of last year and the first few months of this year -- investors had been counting on the company coming up with an answer to this threat, but it didn't materialize.

Except that it did. It just took a while for the market to see it.

The bullish thesis is still plenty strong
There's no single specific catalyst to point to as the driving force behind this stock's sizable bounce back from May's low. Rather, there are several contributing factors that finally reached a collective critical mass.

One of those factors is September's approval of Keytruda Qlex as a treatment for most solid tumors that Keytruda itself is already approved to treat. This is just a subcutaneously injected version of the same drug -- otherwise administered intravenously -- which indirectly extends Keytruda's patent protection. While it remains to be seen how often oncologists will opt for this dosing option now that other oncology drugs are starting to compete with Merck's highly successful anti-PD-1 therapy, certainly some doctors will choose Keytruda Qlex.

Image source: Getty Images.

It's also worth mentioning that the results of a phase 3 trial of pulmonary arterial hypertension treatment Winrevair (released in late September) were very well received. Although the already-approved drug is on track to generate a little over $1 billion in revenue in 2025, as its usefulness continues to widen and interest grows, analysts believe it could produce around $8 billion in annual sales within a few years.

In this vein -- and this is the part of the story investors just weren't appreciating until very recently -- Merck contends that the drugs in its current development pipeline could be producing more than $50 billion worth of yearly revenue by the mid-2030s. None of them by themselves will replace Keytruda's revenue. In the aggregate, though, all of them will more than do so.

Then there are the bullish developments that have always been brewing in the background: acquisitions. In October Merck completed its acquisition of pulmonary disease specialist Verona Pharma. In November, it announced it would be acquiring Cidara Therapeutics for a little over $9 billion, bringing a new flu vaccine candidate into the fold. These are just the pharma company's most recent deals, of course. Merck has a long history of buying the right drugs at the right time -- including Keytruda, which it garnered with its 2009 acquisition of Schering-Plough.

Don't lose perspective
But is the drugmaker's stock a buy, particularly after its 30% run-up just since September's low? I believe so, just as it's been for the better part of the past several years. Shares are still bargain-priced, at less than 12 times next year's projected earnings per share, and its current forward-looking dividend yield of 3.3% is better than you'll find with most dividend-paying blue chips.

It will never be a high-growth investment, to be clear. The pharmaceutical giant, however, is built to make steady forward progress, even if the market as a whole occasionally loses sight of this longevity -- as it did for a while in the middle of last year, and early this year when concern over Keytruda's expiring patents turned into panic.

The thing is, Keytruda isn't the first of Merck's drugs to lose patent protection, and won't be its last. Just as it always has, this company will continue to find and develop new profit centers, such as Keytruda Qlex, some of which will prove to be surprisingly productive. Don't fall into the trap of making more out of the patent cliff than it deserves.

NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Freeport, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Freeport securities. The case is pending in the U.S. District Court for the District of Arizona and is captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243.

Why is Freeport Being Sued For Securities Fraud?

Freeport is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia (“PTFI”). PTFI operates the Grasberg Copper and Gold Mine (“Grasberg”), in which the Indonesian government holds a commercial interest. During the relevant period, Freeport touted its safety procedures, including its use of data and technology as well as behavioral science principles to prevent fatal incidents. It indicated it provides the training, tools, and resources needed to identify risks and consistently apply effective controls.

As alleged, in truth, Freeport overstated its commitment to safety, given that it conducted unsafe mining practices at the Grasberg mine which were reasonably likely to result in worker fatalities.

Why did Freeport’s Stock Drop?

On September 9, 2025, Freeport issued a press release on its PTFI operations. It announced that mining operations in Grasberg had been suspended to evacuate seven team members that were trapped due to a landslide at one of its underground mines. This news caused the price of Freeport stock to drop $2.77 per share, or more than 5.9%, from a closing price of $46.66 per share on September 8, 2025, to $43.89 per share on September 9, 2025.

On September 24, 2025, Freeport issued an update on the incident noting that two of the seven individuals had been fatally injured and that the remaining five team members remained missing. In the same release, Freeport noted that due to the suspension in operations, sales were expected to be 4% lower for copper and approximately 6% lower for gold than July 2025 estimates. This news caused the price of Freeport stock to drop $7.69 per share, or almost 17%, from a closing price of $45.36 per share on September 23, 2025, to $37.67 per share on September 24, 2025.

Then, on September 25, 2025, Bloomberg reported that the incident and halt in production was straining the relationship between Freeport and Indonesia, that “the Jakarta government [had already been] looking to take greater control,” and that government officials may increase its demand for an increased share. This news caused the price of Freeport stock to drop $2.33 per share, or more than 6%, from a closing price of $37.67 per share on September 24, 2025, to $35.34 per share on September 25, 2025.

Finally, on September 28, 2025, an Indonesian news organization reported that the incident was preventable, not just a natural disaster. The article quotes an Indonesian professor stating that “the landslide, often termed a mud rush, is a known flow of mud and rocks from the mine cavity, a risk long associated with certain mining methods.” The professor stated, “[i]n other words, this danger is not new and should have been anticipated from the beginning[.]”

Click here for more information: https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit.

What Can You Do?

If you invested in Freeport you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.